BR112023020832A2 - TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES - Google Patents

TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES

Info

Publication number
BR112023020832A2
BR112023020832A2 BR112023020832A BR112023020832A BR112023020832A2 BR 112023020832 A2 BR112023020832 A2 BR 112023020832A2 BR 112023020832 A BR112023020832 A BR 112023020832A BR 112023020832 A BR112023020832 A BR 112023020832A BR 112023020832 A2 BR112023020832 A2 BR 112023020832A2
Authority
BR
Brazil
Prior art keywords
tcr
binded
multifunctional molecules
molecules
multifunctional
Prior art date
Application number
BR112023020832A
Other languages
Portuguese (pt)
Inventor
Andreas Loew
Gurkan Guntas
Jonathan Hsu
Madan Katragadda
Sangeetha Palakurthi
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of BR112023020832A2 publication Critical patent/BR112023020832A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

moléculas multifuncionais ligadas a tcr e seus usos. são fornecidas neste documento moléculas polipeptídicas multifuncionais compreendendo porções de ligação beta variável de receptor de células t e citocinas e métodos de tratamento de condições ou doenças em um indivíduo usando as mesmas.TCR-linked multifunctional molecules and their uses. Provided herein are multifunctional polypeptide molecules comprising t-cell receptor and cytokine variable beta binding moieties and methods of treating conditions or diseases in an individual using the same.

BR112023020832A 2021-04-08 2022-04-07 TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES BR112023020832A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172468P 2021-04-08 2021-04-08
PCT/US2022/023922 WO2022216993A2 (en) 2021-04-08 2022-04-07 Multifuntional molecules binding to tcr and uses thereof

Publications (1)

Publication Number Publication Date
BR112023020832A2 true BR112023020832A2 (en) 2023-12-19

Family

ID=83546591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020832A BR112023020832A2 (en) 2021-04-08 2022-04-07 TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES

Country Status (9)

Country Link
EP (1) EP4320147A2 (en)
JP (1) JP2024515591A (en)
KR (1) KR20240004462A (en)
CN (1) CN117597359A (en)
AU (1) AU2022255506A1 (en)
BR (1) BR112023020832A2 (en)
CA (1) CA3214757A1 (en)
GB (1) GB2623199A (en)
WO (1) WO2022216993A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081381A1 (en) * 2022-10-12 2024-04-18 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN116554356B (en) * 2023-05-16 2024-01-23 武汉大学 Fusion protein of hyper IL-15, sCD4 and Fc and application thereof

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861745A (en) 1906-11-21 1907-07-30 Jefferson D Maxwell Hydraulic dredging apparatus.
DE2860709D1 (en) 1977-06-28 1981-08-27 Sandoz Ag 1-substituted aminoindolines, process for their production and pharmaceutical compositions containing them
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
JP3771253B2 (en) 1988-09-02 2006-04-26 ダイアックス コープ． Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
PT100379B (en) 1991-04-10 1999-01-29 Scripps Research Inst LIBRARIES OF HETERODYMERIC RECEPTORS USING FAGOMIDEOS
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP1024191B8 (en) 1991-12-02 2008-11-05 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3980657B2 (en) 1992-06-26 2007-09-26 生化学工業株式会社 Chondroitinase ABC, process for producing the same and pharmaceutical composition
PT1498427E (en) 1992-08-21 2010-03-22 Univ Bruxelles Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE404683T1 (en) 1992-09-25 2008-08-15 Aventis Pharma Sa ADENOVIRUS VECTORS FOR TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY IN THE BRAIN
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0985039T3 (en) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Artificial antibody polypeptides
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU4499499A (en) 1999-04-01 2000-10-23 Innogenetics N.V. A polypeptide structure for use as a scaffold
DE19932688B4 (en) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design of beta-sheet proteins of gamma-II-crystalline antibody-like
GEP20053685B (en) 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
SI2857516T1 (en) 2000-04-11 2017-09-29 Genentech, Inc. Multivalent antibodies and uses therefor
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
ATE477280T1 (en) 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
US20040009530A1 (en) 2002-01-16 2004-01-15 Wilson David S. Engineered binding proteins
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
JP2006512895A (en) 2002-06-28 2006-04-20 ドマンティス リミテッド Ligand
CN101537180B (en) 2002-07-18 2016-02-10 莫鲁斯有限公司 The recombinant production of mixtures of antibodies
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
PL2405015T3 (en) 2003-03-05 2016-09-30 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
ATE414106T1 (en) 2003-06-30 2008-11-15 Domantis Ltd PEGYLATED SINGLE DOMAIN ANTIBODIES (DAB)
CN1897966A (en) 2003-10-20 2007-01-17 比奥根艾迪克Ma公司 Therapeutic regimens for baff antagonists
CN1980957A (en) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
PT1773885E (en) 2004-08-05 2010-07-21 Genentech Inc Humanized anti-cmet antagonists
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
SI1797127T1 (en) 2004-09-24 2017-09-29 Amgen Inc. Modified fc molecules
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
WO2006076691A2 (en) 2005-01-12 2006-07-20 Medarex, Inc. Irta-2 antibodies and their uses
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7431380B1 (en) 2005-02-24 2008-10-07 Theodore Allen Buresh Louver kit
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
SI2439273T1 (en) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (en) 2005-07-01 2008-08-20 米德列斯公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
KR101866623B1 (en) 2005-11-28 2018-07-04 젠맵 에이/에스 Recombinant monovalent antibodies and methods for production thereof
ES2395969T3 (en) 2006-03-24 2013-02-18 Merck Patent Gmbh Genetically modified heterodimeric protein domains
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
KR101586617B1 (en) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. Antibodies to human programmed death receptor PD-1
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
CN107488228A (en) 2008-04-11 2017-12-19 中外制药株式会社 The antigen binding molecules combined repeatedly with the antigen of multiple molecules
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
PE20110435A1 (en) 2008-08-25 2011-07-20 Amplimmune Inc ANTAGONIST COMPOSITIONS OF PD-1
JP2012510429A (en) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド PD-1 antagonist and method of use thereof
UA109108C2 (en) 2008-12-09 2015-07-27 Дженентек, Інк. Anti-pd-ll antibody and its use to enhance t-cell function
ES2629337T3 (en) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies against PD-1 and antibodies against PD-L1 and uses thereof
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
AU2010232682A1 (en) 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MX2012006406A (en) 2009-12-04 2012-07-25 Genentech Inc Multispecific antibodies, antibody analogs, compositions, and methods.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN114246952A (en) 2010-06-08 2022-03-29 基因泰克公司 Cysteine engineered antibodies and conjugates
EP2581113B1 (en) 2010-06-11 2018-05-09 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
PL2606064T3 (en) 2010-08-16 2015-07-31 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies comprising Fv fragments stabilized by disulfides
CA2807269A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
UY33827A (en) 2010-12-22 2012-07-31 Abbott Lab MEDIUM-IMMUNOGLOBULIN UNION PROTEINS AND ITS USES
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012118622A1 (en) 2011-02-19 2012-09-07 Baylor Research Institute Diagnostic and therapeutic uses for b cell maturation antigen
SG10201602371VA (en) 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CN107936121B (en) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
DK2728002T3 (en) 2011-06-30 2022-04-04 Chugai Pharmaceutical Co Ltd HETERODIMERIZED POLYPEPTIDE
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
LT2748201T (en) 2011-08-23 2018-02-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PT2768857T (en) 2011-10-19 2020-01-27 Novimmune Sa Methods of purifying antibodies
PL2773671T3 (en) 2011-11-04 2022-01-24 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
DK2785375T3 (en) 2011-11-28 2020-10-12 Merck Patent Gmbh ANTI-PD-L1 ANTIBODIES AND USES THEREOF
WO2013096291A2 (en) 2011-12-20 2013-06-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR101814370B1 (en) 2011-12-27 2018-01-12 재단법인 생물기술개발중심 Light chain-bridged bispecific antibody
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
ES2728301T3 (en) 2012-03-13 2019-10-23 Novimmune Sa Easily isolated bispecific antibodies with native immunoglobulin format
DK2825553T3 (en) 2012-03-14 2018-09-24 Regeneron Pharma : Multispecific antigen binding molecules and applications thereof
PT2838918T (en) 2012-04-20 2019-08-23 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
MX2019001355A (en) 2012-05-10 2023-01-17 Bioatla Llc Multi-specific monoclonal antibodies.
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
RU2014149681A (en) 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг MULTIPLE SPECIFICITY ANTIBODIES
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
BR112015000167B1 (en) 2012-07-06 2021-11-23 Genmab B.V. DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
EP2904016B1 (en) 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
EP2940135B9 (en) 2012-12-27 2021-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
EP2954056A4 (en) 2013-02-08 2016-09-21 Stemcentrx Inc Novel multispecific constructs
CA2904230A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Engager cells for immunotherapy
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
WO2014150973A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
PL2992010T3 (en) 2013-04-29 2021-08-23 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US20160114057A1 (en) 2013-05-24 2016-04-28 Zyeworks Inc. Modular protein drug conjugate therapeutic
RU2655439C2 (en) 2013-05-31 2018-05-28 Займворкс Инк. Heteromultimers with reduced or silenced effector function
AR096687A1 (en) 2013-06-24 2016-01-27 Genentech Inc ANTI-FCRH5 ANTIBODIES
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
BR112016006197B1 (en) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
UA120753C2 (en) 2013-12-17 2020-02-10 Дженентек, Інк. Anti-cd3 antibodies and methods of use
MX2016008540A (en) 2014-01-15 2016-09-26 Hoffmann La Roche Fc-region variants with modified fcrn-binding properties.
JP6786392B2 (en) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Fc region mutant with modified FcRn binding properties and retained protein A binding properties
KR20160104636A (en) 2014-01-15 2016-09-05 에프. 호프만-라 로슈 아게 Fc-region variants with improved protein a-binding
US20170058045A1 (en) 2014-02-21 2017-03-02 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
AU2015254526B2 (en) 2014-04-30 2020-04-30 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Humanized antibodies against CD269 (BCMA)
EP4026850A1 (en) 2014-05-28 2022-07-13 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
EP3160994A2 (en) 2014-06-27 2017-05-03 Innate Pharma Multispecific antigen binding proteins
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
DK3177643T3 (en) 2014-08-04 2019-07-15 Hoffmann La Roche Bispecific T cell activating antigen binding molecules
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
AR102522A1 (en) 2014-11-06 2017-03-08 Hoffmann La Roche FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A
SI3215528T1 (en) 2014-11-06 2019-11-29 Hoffmann La Roche Fc-region variants with modified fcrn-binding and methods of use
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN107207609B (en) 2014-11-20 2022-07-19 豪夫迈·罗氏有限公司 Common light chains and methods of use
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
EP3227328B1 (en) 2014-12-05 2022-10-05 Merck Patent GmbH Domain-exchanged antibody
PT3226897T (en) 2014-12-05 2021-04-13 Eureka Therapeutics Inc Antibodies targeting b-cell maturation antigen and methods of use
BR112017013189B1 (en) 2015-01-08 2024-03-05 Genmab A/S TNF RECEPTOR BINDING AGONISTIC AGENTS
AU2016206707A1 (en) 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
SG11201705116SA (en) 2015-01-20 2017-08-30 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CA2979486A1 (en) 2015-03-13 2016-09-22 Novimmune Sa Methods of purifying bispecific antibodies
LT3283527T (en) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. Combination therapy for cancer
JP6913025B2 (en) 2015-04-13 2021-08-04 ファイザー・インク Therapeutic antibodies and their use
CA2986928A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
ES2812303T3 (en) 2015-07-10 2021-03-16 Merus Nv Antibody that binds to human CD3
BR112018001161A2 (en) 2015-07-23 2018-09-18 Inhibrx Lp multispecific and multivalent gitr-binding fusion proteins
PT3331910T (en) 2015-08-03 2020-03-24 Engmab Sarl Monoclonal antibodies against bcma
PL3337824T3 (en) 2015-08-17 2021-04-19 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CN114127113A (en) * 2019-02-21 2022-03-01 马伦戈治疗公司 Multifunctional molecules binding to calreticulin and uses thereof
WO2021172601A1 (en) * 2020-02-24 2021-09-02 엘지전자 주식회사 Method and apparatus for transceiving and receiving wireless signal in wireless communication system

Also Published As

Publication number Publication date
GB202315700D0 (en) 2023-11-29
AU2022255506A1 (en) 2023-11-09
CN117597359A (en) 2024-02-23
WO2022216993A3 (en) 2022-11-17
JP2024515591A (en) 2024-04-10
CA3214757A1 (en) 2022-10-13
EP4320147A2 (en) 2024-02-14
WO2022216993A2 (en) 2022-10-13
GB2623199A (en) 2024-04-10
KR20240004462A (en) 2024-01-11

Similar Documents

Publication Publication Date Title
BR112023020832A2 (en) TCR-BINDED MULTIFUNCTIONAL MOLECULES AND THEIR USES
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
BR112022014623A2 (en) ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF
EA201992131A1 (en) HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
MX2019003899A (en) Compositions and methods for t-cell receptors reprogramming using fusion proteins.
CL2020000216A1 (en) Anti-ctla-4 antibodies and their uses.
BR112019005944A2 (en) antibodies that bind to interleukin 2 and their uses
BR112021005184A8 (en) DUAL-ACTING CD1D IMMUNOGLOBULIN
MX2018008840A (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases.
WO2016187220A3 (en) Anti-ror1 antibodies
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EA202092032A1 (en) T-CELL RECEPTOR SPECIFIC FOR NY-ESO-1 / LAGE-1 AND ITS APPLICATIONS
BR112018005445A2 (en) optimized anti-cd3 bispecific antibodies and uses thereof
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
MX2020008075A (en) Anti-ctla4 antibodies and methods of making and using the same.
BR112019024654A2 (en) binding protein nkg2d, cd16 and ror1 or ror2
BR112017002342A2 (en) new antibodies and their uses
BR112016016699A2 (en) HUMAN ANTIBODIES TO PD-1
BR112019000436A2 (en) anti-pd-1 antibodies, production method and method of use
ECSP12012211A (en) COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF)
BRPI0821658B8 (en) human monoclonal antibody or an antigen-binding fragment thereof that binds to hnkg2d and its uses
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
CY1121347T1 (en) Fusion PROTEIN
BR112021019471A2 (en) Immunotherapeutic compositions and their use
BR112021012667A2 (en) Anti-pd-1 binding proteins and methods of using them